Lupin is currently trading at Rs. 759.10, up by 12.00 points or 1.61% from its previous closing of Rs. 747.10 on the BSE.
The scrip opened at Rs. 745.00 and has touched a high and low of Rs. 760.00 and Rs. 741.25 respectively. So far 11410 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 697.30 on 19-Jun-2019.
Last one week high and low of the scrip stood at Rs. 785.00 and Rs. 741.25 respectively. The current market cap of the company is Rs. 34177.39 crore.
The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.66% and 14.38% respectively.
Lupin has won the Engineering News-Record's (ENR) Global Best Project Award of Merit in the Manufacturing category. The award was given to Lupin's Oral Solid Dosage (OSD) and Injectable Pharmaceutical Manufacturing Facility at Nagpur, India.
The ENR Global Best Projects Awards are annual awards given by ENR globally as part of an annual competition that identifies and honours the best project teams behind outstanding design and construction efforts. Lupin's OSD and Injectable facility at Nagpur is Lupin's latest and most advanced manufacturing unit commissioned in 2018.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1938.85 |
| Dr. Reddys Labs. | 1269.80 |
| Cipla | 1441.70 |
| Zydus Lifesciences | 1159.85 |
| Lupin | 2502.90 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: